Team
Ms. Hollingsworth is one of the leaders of the entrepreneurial and life sciences communities and serves on various industry and community boards, including DS Biopharma, Talee Bio, the University City Science Center, the Kimmel Center for the Performing Arts, and Breastcancer.Org.
Dr. Lau earned an MBA from the Wharton School of Business at the University of Pennsylvania, a PhD in Neuroscience from the University of Cincinnati College of Medicine and a BS in Bioengineering from the University of Pennsylvania.
Prior to joining Militia Hill Ventures, Ms. D’Oyley-Gay was Vice President and Associate General Counsel at GlaxoSmithKline for 14 years, supporting GlaxoSmithKline’s global corporate strategy and business development groups. In 2009, Ms. D’Oyley-Gay received the Healthcare Businesswomen’s Association Rising Star Award for GlaxoSmithKline. Prior to joining GlaxoSmithKline, Ms. D’Oyley-Gay was in private practice, including at Reed Smith LLP, representing pharmaceutical companies and healthcare systems in transactional and healthcare regulatory matters, and at a boutique health law firm, representing physician practice groups and affiliated ventures.
Ms. D'Oyley-Gay obtained a Juris Doctorate Degree from the University of Pennsylvania Law School and a Bachelor of Science Degree in Economics from the University of Delaware.
Bill remains an active member of the scientific community at-large. A co-author on more than 70 primary research and review articles, he is a former Councilor of the Society for Neuroscience and is active in science policy, diversity and professional development. He serves on the Advisory Council for Brown University’s Carney Institute for Brain Science and is an At-Large Member of the Coalition for the Life Sciences Board of Directors. Bill graduated from Swarthmore College, earned his PhD from Brown University and carried out his postdoctoral research at the Keck Center for Integrative Neuroscience at the University of California at San Francisco.
Dr. Saporito has over 25 years experience in the biopharmaceutical industry. During his career, Dr. Saporito has enabled the translation of discovery stage assets to drug development and clinical candidates.
Dr. Saporito started his career at Cephalon Inc. where he established a research lab studying mechanisms of neurodegeneration in Parkinson’s disease, identified novel kinases involved in the neurodegenerative process in this disease and transitioned experimental drugs into development and clinical trials. Dr. Saporito also headed the biology research group at Locus Pharmaceuticals and cofounded Melior Discovery where he was Chief Scientific Officer and a member of the board of directors.
Dr. Saporito is a member of several non-profit boards and consults for and advises biopharmaceutical companies, venture capital groups and investment banks. Dr. Saporito is a graduate of Juniata College, obtained his Ph.D in Pharmacology at University of the Sciences in Philadelphia and continued his training as a postdoctoral fellow at Robert Wood Johnson Medical School in the Department of Neurology.
diligence and company evaluation and formation. Dr. Willenbucher has more than 20 years of experience in building and leading technology-based teams across a variety of therapeutic areas and platforms. Prior to MHV, he was the Vice President and Head of Janssen Cell Therapy (a part of Johnson & Johnson’s family of companies), where he was responsible for leadership and coordination of all aspects of cell therapy, including programs in retinal disease, cardiac disease, diabetes, and oncology. Dr. Willenbucher also served as Head of the Janssen Incubator, an internal, entrepreneurial group within the Janssen research and development group. The Janssen Incubator nurtured highly innovative programs through venture team formation and a novel operating model that included assistance from internal and external experts. Prior to his most recent roles at Janssen, Dr. Willenbucher served in other positions within Johnson & Johnson, including Executive Director of Pharmaceutical Group Business Development and Strategic Development Leader for the Gastro-intestinal Therapeutic Area. He began his
career in industry with Otsuka America Pharmaceuticals.
Dr. Willenbucher earned his MD from the Columbia University College of Physicians
and Surgeons and an MBA from the Wharton School of Business at the University of
Pennsylvania. He is a board-certified internist and gastroenterologist and previously served as an Associate Professor of Medicine at the University of California, San Francisco.
Dr. Yuen was the Director of Clinical Research at Merck & Co., working on CNS and pain indications and later Vice President of Clinical Development at Johnson & Johnson. While at Johnson & Johnson Dr. Yuen served as the therapeutic area head for CNS and the head of clinical development at a monoclonal antibodies and vaccines joint venture between Johnson & Johnson and Elan. Eric later served as Chief Medical Officer for Ultragenyx, a start-up company focused on rare genetic diseases, and as VP Clinical Development at BioClin Therapeutics, a start-up focused on the rare genetic disorder achondroplasia (dwarfism) and bladder cancer. Dr. Yuen continues to serve as a consultant to biotechnology and pharmaceutical companies.
Earlier in his career, Dr. Yuen was an assistant professor of neurology at the University of Washington where he conducted clinical research in rare disorders such as ALS and muscular dystrophies. Dr. Yuen completed his undergraduate education at Stanford University, M.D. from the University of Chicago, Pritzker School of Medicine, neurology residency at UCSF, and a post-doc in the lab studying neurotrophic factor signaling at UCSF.
B.A. received his AB in Human Development and Regenerative Biology and a secondary degree in Global Health and Health Policy from Harvard University. While at Harvard, B.A. conducted research in cardiac optogenetics and in post-traumatic cognitive development.
Matt received his BS in Neuroscience from Brown University. While at Brown, Matt conducted neurobiology research focused on plasticity in the spinal cord and was a varsity swimmer.
Mike began his career in Independent Minor League Baseball, pitching for the Joliet Slammers of the Frontier League. After retiring from baseball, Mike spent several years in Pennsylvania government and politics, reporting directly to the Chief of Staff in Governor Tom Wolf’s administration and transition, and holding senior staff roles on Katie McGinty’s campaigns for US Senate and PA Governor. Mike join MHV in the spring of 2017 and took the lead role in PhillyBio at the start of 2018.
Mike was born and raised in Philadelphia. He received his B.A. in Government with a concentration in American Politics from Wesleyan University. While at Wesleyan, Mike was captain of the varsity baseball team and a social chair for his fraternity, Delta Kappa Epsilon.